CN117586938A - 一种高效合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 - Google Patents
一种高效合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 Download PDFInfo
- Publication number
- CN117586938A CN117586938A CN202410069807.4A CN202410069807A CN117586938A CN 117586938 A CN117586938 A CN 117586938A CN 202410069807 A CN202410069807 A CN 202410069807A CN 117586938 A CN117586938 A CN 117586938A
- Authority
- CN
- China
- Prior art keywords
- neotetraose
- lactoyl
- escherichia coli
- gene
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 38
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 13
- 238000010276 construction Methods 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 28
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 16
- 239000008101 lactose Substances 0.000 claims abstract description 16
- 238000012258 culturing Methods 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 238000000855 fermentation Methods 0.000 claims description 24
- 230000004151 fermentation Effects 0.000 claims description 24
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 12
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 12
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 5
- 101100345994 Aspergillus oryzae (strain ATCC 42149 / RIB 40) mns1B gene Proteins 0.000 claims description 4
- 101100176023 Bacillus subtilis (strain 168) glsA1 gene Proteins 0.000 claims description 4
- 101100346210 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) pmi1 gene Proteins 0.000 claims description 4
- 101100398785 Streptococcus agalactiae serotype V (strain ATCC BAA-611 / 2603 V/R) ldhD gene Proteins 0.000 claims description 4
- 101100075926 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) pmi gene Proteins 0.000 claims description 4
- 101100386830 Zymomonas mobilis subsp. mobilis (strain ATCC 31821 / ZM4 / CP4) ddh gene Proteins 0.000 claims description 4
- 229940041514 candida albicans extract Drugs 0.000 claims description 4
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 4
- 229910000388 diammonium phosphate Inorganic materials 0.000 claims description 4
- 235000019838 diammonium phosphate Nutrition 0.000 claims description 4
- 101150073761 glsA gene Proteins 0.000 claims description 4
- 101150026107 ldh1 gene Proteins 0.000 claims description 4
- 101150041530 ldha gene Proteins 0.000 claims description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 4
- 101150026430 manA gene Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 101150111581 pflB gene Proteins 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- 101150033131 sthA gene Proteins 0.000 claims description 4
- 239000011573 trace mineral Substances 0.000 claims description 4
- 235000013619 trace mineral Nutrition 0.000 claims description 4
- 239000012137 tryptone Substances 0.000 claims description 4
- 101150078236 wzzE gene Proteins 0.000 claims description 4
- 239000012138 yeast extract Substances 0.000 claims description 4
- 239000012880 LB liquid culture medium Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 108090000992 Transferases Proteins 0.000 abstract description 7
- 108010046068 N-Acetyllactosamine Synthase Proteins 0.000 abstract description 6
- 238000010362 genome editing Methods 0.000 abstract description 5
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 4
- 102000004357 Transferases Human genes 0.000 abstract description 4
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 abstract description 4
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 4
- 239000008103 glucose Substances 0.000 abstract description 4
- 239000002243 precursor Substances 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 9
- 230000010354 integration Effects 0.000 description 7
- 210000004251 human milk Anatomy 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010073324 Glutaminase Proteins 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- RNQVGVKGGAODSC-MEXJFSEESA-N 1-[(3R,4R,5R,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-4-yl]ethanone Chemical compound C(C)(=O)[C@]1([C@H](C(O)O[C@@H]([C@H]1O)CO)N)O RNQVGVKGGAODSC-MEXJFSEESA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 108010001539 D-lactate dehydrogenase Proteins 0.000 description 2
- 102000009127 Glutaminase Human genes 0.000 description 2
- 108091022912 Mannose-6-Phosphate Isomerase Proteins 0.000 description 2
- 108010001609 NADP Transhydrogenases Proteins 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 235000018660 ammonium molybdate Nutrition 0.000 description 2
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 108010008221 formate C-acetyltransferase Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 101150111330 glmU gene Proteins 0.000 description 2
- 108010084034 glucosamine-1-phosphate acetyltransferase Proteins 0.000 description 2
- 108020002326 glutamine synthetase Proteins 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- ISPYRSDWRDQNSW-UHFFFAOYSA-L manganese(II) sulfate monohydrate Chemical compound O.[Mn+2].[O-]S([O-])(=O)=O ISPYRSDWRDQNSW-UHFFFAOYSA-L 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021654 trace metal Inorganic materials 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RNZCSKGULNFAMC-UHFFFAOYSA-L zinc;hydrogen sulfate;hydroxide Chemical compound O.[Zn+2].[O-]S([O-])(=O)=O RNZCSKGULNFAMC-UHFFFAOYSA-L 0.000 description 2
- 101150038172 1.2 gene Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000048193 Mannose-6-phosphate isomerases Human genes 0.000 description 1
- 102000000818 NADP Transhydrogenases Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108010064177 glutamine synthetase I Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- -1 lgtA-lgtB Proteins 0.000 description 1
- 101150018810 lgtB gene Proteins 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01004—Glucosamine-phosphate N-acetyltransferase (2.3.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01022—Lactose synthase (2.4.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
- C12Y501/03002—UDP-glucose 4-epimerase (5.1.3.2), i.e. UDP-galactose 4-epimerase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种高效合成乳酰‑N‑新四糖的重组大肠杆菌的构建方法及应用,通过筛选高效的β‑1,3‑乙酰葡萄糖胺转移酶及β‑1,4‑半乳糖基转移酶并异源引入大肠杆菌BL21(DE3)中,对其进行基因组多位点的基因编辑,外加受体乳糖,构建高效生产乳酰‑N‑新四糖的菌株;进而优化其前体UDP‑乙酰氨基葡萄糖和UDP‑半乳糖的供应,增强乳糖的积累进一步提高乳酰‑N‑新四糖的产量。通过重组大肠杆菌进行培养和发酵,能够高效合成得到乳酰‑N‑新四糖,并且能够进一步提高所得产物的生物安全性,适用于制备食品或药物。
Description
技术领域
本发明属于代谢工程领域,尤其是涉及一种高效合成乳酰-N-新四糖的重组大肠杆菌的构建方法及应用。
背景技术
母乳中富含人体所需的六大营养物质,且易于新生儿消化吸收,是新生儿最理想、最优质的天然食品;人乳寡糖(HMOs)是母乳中重要的活性因子,主要包括唾液酸化、岩藻糖基化和非岩藻糖基化三大类,其中非岩藻糖基化寡糖LNnT含量相对丰富,报道表明其能够保护婴幼儿肠道菌群、促进免疫系统的发育、提高认知记忆能力;因此高效合成LNnT是生产更接近母乳的配方奶粉的重要目标。
目前乳酰-N-新四糖的人工合成主要采用化学合成法和酶法,微生物合成法的应用较少,而化学法和酶法成本较高且效率低;因此,微生物合成乳酰-N-新四糖受到科研学者的广泛关注。此前,已有研究对大肠杆菌、枯草芽孢杆菌进行基因改造以合成乳酰-N-新四糖,但大多数都以导入游离质粒的方式增加产量,菌株表达不稳定,基因组整合改造的报道相对较少且难以达到规模化生产的要求,因而构建更高效的工程菌株以提高乳酰-N-新四糖的产量对母乳寡糖的研究。
发明内容
为解决上述技术问题,本发明提供一种高效合成乳酰-N-新四糖的重组大肠杆菌的构建方法及应用。
本发明采用的技术方案是:一种高效合成乳酰-N-新四糖的重组大肠杆菌,在底盘宿主细胞中插入lgtA和lgtB基因。
优选地,敲除其基因组中lacZ, wzzE, manA, ldhA, pflB, sthA glsA, glsB基因中的一种或多种,还插入或过表达galE和/或glmU基因。
优选地,以底盘宿主大肠杆菌为出发菌株,敲除lacZ,并在此位点整合lgtA;敲除wzzE,并在此位点整合galE及lgtB;敲除manA,并在此位点过表达glmU;敲除ldhA,并在此位点过表达lgtA及lgtB;敲除pflB,并在此位点过表达lgtB;敲除sthA,并在此位点过表达glnA;敲除glsA,并在此位点过表达lgtA;敲除glsB,并在此位点过表达lgtB,得到高效合成乳酰-N-新四糖的重组大肠杆菌。
优选地,整合或过表达基因使用23100启动子进行转录。
优选地,lgtA核苷酸序列如SEQ ID NO.1所示,lgtB核苷酸序列如SEQ ID NO.2所示。
一种乳酰-N-新四糖的制备方法,通过重组大肠杆菌培养并发酵得到。
优选地,重组大肠杆菌经种子培养获得种子液,再将种子液接种于发酵体系中,获得产乳酰-N-新四糖的发酵液;
种子培养基为LB液体培养基,将种子液接入发酵体系,于37℃,180 rpm条件下,培养至OD600为12时,加入10 g/L乳糖,每12 h补加10 g/L乳糖和20 g/L甘油,培养至72 h。
优选地,发酵培养基的配方为:胰蛋白胨2 g/L,酵母提取物4 g/L,甘油20 g/L,磷酸二氢钾13.5 g/L,磷酸氢二铵1.4 g/L,柠檬酸1.7 g/L,七水硫酸镁1.5 g/L,微量元素10ml/L。
乳酰-N-新四糖的制备方法制备得到的乳酰-N-新四糖在食品或药物中的应用。
本发明具有的优点和积极效果是:选出一种高效的β-1,3-乙酰葡萄糖胺转移酶和一种β-1,4-半乳糖基转移酶并异源引入大肠杆菌BL21(DE3)中,并表达来源于大肠杆菌MG1655的galE基因,外加受体乳糖,构建出可以合成乳酰-N-新四糖的菌株;优化其合成前体UDP-乙酰氨基葡萄糖和UDP-半乳糖的代谢途径,提高供体和受体的积累,进一步提高乳酰-N-新四糖的产量;另外,通过本发明方法制备得到的重组工程菌,发酵过程无需添加抗生素,进一步提升了制备得到的乳酰-N-新四糖的生物安全性。
附图说明
图1为本发明重组大肠杆菌合成 乳酰-N-新四糖的代谢途径;
图2为对宿主菌依次进行基因编辑后摇瓶发酵乳酰-N-新四糖的产量比较;
图3为本发明重组大肠杆菌在5L发酵罐中产物、底物动态变化以及生长曲线。
具体实施方式
下面结合附图对本发明的实施例做出说明。
本发明涉及一种高效合成乳酰-N-新四糖的重组大肠杆菌,以大肠杆菌BL21(DE3)为底盘宿主细胞,将β-1,3-乙酰葡萄糖胺转移酶及β-1,4-半乳糖基转移酶并异源引入大肠杆菌BL21(DE3)中,对其进行基因组多位点的基因编辑,优化其合成前体UDP-乙酰氨基葡萄糖和UDP-半乳糖的代谢途径,提高供体和受体的积累,构建高效生产乳酰-N-新四糖的菌株;外源添加受体乳糖,以甘油和乳糖为底物,对重组工程菌进行培养和发酵,能够高效获得乳酰-N-新四糖。
为了进一步优化其前体UDP-乙酰氨基葡萄糖和UDP-半乳糖的供应,增强乳糖的积累进一步提高乳酰-N-新四糖的产量,还可对旁路合成路径中的关键酶进行编辑敲除,过表达利于合成乳酰-N-新四糖的酶,提高乳酰-N-新四糖合成路径在重组工程菌中的比重,如图1所示,从而实现高效合成乳酰-N-新四糖的目的。本发明某些实施例中,可敲除其基因组中lacZ, wzzE, manA, ldhA, pflB, sthA glsA, glsB基因中的一种或多种,除了插入lgtA和lgtB外, 还可插入或过表达galE和glmU。
其中,β-半乳糖苷酶基因lacZ的ID为8181469,肠杆菌共同抗原多糖共聚酶基因wzzE的ID为8182211,甘露糖-6-磷酸异构酶基因manA的ID为8181948,D-乳酸脱氢酶基因ldhA的ID为8181329,丙酮酸甲酸裂解酶基因pflB的ID为8182293,吡啶核苷酸转氢酶基因sthA的ID为8183552,谷氨酰胺酶基因glsA的ID为8179676,谷氨酰胺酶基因glsB的ID为8181212;
葡萄糖胺-1-磷酸乙酰转移酶基因glmU的ID为8183714,UDP-葡萄糖4-差向异构酶基因galE的ID为945354,谷氨酰胺合成酶基因glnA的ID为8181063;β-1,3-乙酰葡萄糖胺转移酶LgtA来源于奈瑟氏球菌(Neisseria sp.),优化后的核苷酸序列如SEQ ID NO.1所示;β-1,4-半乳糖基转移酶LgtB来源于流感嗜血杆菌(Haemophilus influenzae),优化后的核苷酸序列如SEQ ID NO.2所示。
SEQ ID NO.1:
ATGCAGCTGCTGGTGAGCGTGCTGATTTGCGCGTATAACGTGGAAAAATATTTTGCGCAGGCGCTGGATGCGGTGGTGCGCCAGACCTGGCGCAACTTAGAAATTTTTATTGTGGATGATGGCAGCACCGATGGCACCCTGGTGATTGCGAAAGATTTTCAGAAACGCGATAGCCGCATTAAAATTCTGGCGCAGGCCCAGAACAGCGGCCTGATTCCGAGCTTGAATACTGGCCTGGAAGAGATTATTAAGAGCGGCAAAGGCGAATATATTGCGCGCACCGATGCGGATGATATTGCGAGCCCGGATTGGATTGAGAAGATTGTGAGCGCGATGGAAAAAGATCGCGATATTATTGCGATGGGCGCGTGGCTGGAAGTGCTGAGCGAAGAAGGCGATGGCAATCGCTTAGCGCGCCATCATCGTCATGGCGCGATTTGGGATAAACCGACCCGCCATGAAGATATTGCGGCGGTGTTTCCGTTTGGCAACCCGATTCATAACAACACCATGATTATGCGCCGCAGCGTGATTGAAGGCGGCCTGCGCTATGATACCGAATGCGATTGGGCGGAAGATTATAAATTTTGGTACGAAGTGAGCAAACTGGGCCGCCTGGCGTATTATCCGGAAGCGCTGGTGAAATATCGCTTTCATGCGAACCAGGTTAGCAGCAAATATAGCACCCGCCAGCATGAAACCGCGCAGGGCATTCAGAAGACCATTCGCAACGATTTTCTGCAAAGCATTGGCTTTAAAACCCGCTTTGATAGCCTGGAATATCGCCAGACCAAAGCGGTGGCGTATGAACTGCTGGAAAAGGATCTGCCGGAAGATGACTTTGAACGCGTGCGCCATTTTCTGTATCAGTGCTTTAAATGGACCGATACCCCGCCGAGCAACGCATGGTTAGATTTTGCGGCGGATGGCAAAATGCGCCGCCTGTTTACCATGCGCCAGTATTTTAGCATTCTGCGCCGCCTGCTGAAAAACCGCTAA
SEQ ID NO.2:
ATGAGCGCGATTGAGAACATCGTCATCAGCATGGAAAACGCGACCGAACGTCGTAAACACATCACCAAGCAGTTCGAGAGCAAGAACCTGAGCTTCAGCTTCTTCAACGCGTACACCTACCAGAGCATTAACCAGAGCATCAACCAGAGCATCAACCAGAGCAACAGCATCCTGCACAACATCGAAGAGAGCCGTATTCTGACCAAAGGCGAGAAAGGTTGCCTGATTAGCCACTTCCTGCTGTGGAACAAGTGCGTTAACGAGAACCTGGAGTACCTGAAAATTTTTGAGGACGACGTTATTCTGGGCGAAAACGCAGAAGTCTTCCTGAACCAGAACGAGTGGCTGAAAACCCGCTTCGACTTCAACGACATCTTCATCATCCGCCTGGAAACCTTTCTGCGTCCGGTTAAACTGGAGAAGCAGACCAAAATCCCGCCGTTTAACAGCCGCAACTTCGATATCCTGAAAAGCACCCACTGGGGTACCGCAGGTTATATCATTAGCCAGGGCGCAGCGAAATACGTCATCGAATATCTGAAGAACATCCCGAGCGACGAAATTGTTGCGGTCGACGAACTGATCTTCAACAAGCTGGTCGACGTCGACAACTACATCGTCTACCAGCTGAACCCGGCAATTTGTATCCAGGAACTGCAGGCGAACCAGAGTAAAAGCGTTCTGACCTCTGGCCTGGAAAAAGAACGTCAGAAACGTCCGAAGATCCGCAAGAAGAAGACCCTGAAACAGCGTCTGACCCGCATCAAAGAGAACATCATCCGCGCACTGAACCGTAAAAAGTGGAAAGAACAGCAGCGCATCAAAGAGATGCAGGGCAAAGAAATCGTTCGCTTCATGTAA
构建重组大肠杆菌时,采用两步同源重组方法进行基因编辑,实现无痕敲除。使用氯霉素抗性基因与蔗糖敏感基因sacB通过重叠延伸PCR进行融合,第一步将cat-sacB片段整合到缺失基因位点,筛选出能够在氯霉素平板上生长的菌落进行PCR鉴定;第二步利用sacB基因的蔗糖聚合致死作用反筛出不含cat-sacB片段的菌株,再次进行PCR鉴定并测序验证,得到目的基因整合成功的菌株。上述第二步同源重组的片段通过重叠延伸PCR进行融合,将待敲除基因上游300-500bp和下游300-500bp分别融合到待插入基因片段的上游和下游,再通过重叠延伸PCR进行待敲除基因的敲除以及待插入基因片段的插入,其中待插入基因片段可包括一个基因或多个基因,还可在其5`端插入23100启动子;
以wzzE位点过表达galE和lgtB为例,取wzzE基因上游500bp同源臂与23100-galE融合,lgtB与wzzE基因下游500bp同源臂融合,再将两段产物再次融合即可。通过这样的构建方法,能够避免影响底盘宿主其他功能,有目的的进行敲除和整合,避免由于外源基因的介入,影响大肠杆菌内其他功能。
本发明某些实施例中,为了进一步确保整合的基因或过表达的基因能够高效表达,所有整合位点过表达的基因均使用23100启动子进行转录,23100启动子序列如SEQ IDNO.3所示。
SEQ ID NO.3:ttgacggctagctcagtcctaggtacagtgctagcaaggagatatact
构建得到的重组大肠杆菌能够用于高效合成乳酰-N-新四糖,经种子培养获得种子液,再将种子液接种于发酵体系中,获得产乳酰-N-新四糖的发酵液。发酵体系中的碳源为甘油,以乳糖为底物合成乳酰-N-新四糖;种子培养基为LB液体培养基,种子培养的条件为37℃,180 rpm,摇瓶培养14 h;将种子液接入发酵体系,于37℃,180 rpm条件下,培养至OD600为12时,加入10 g/L乳糖,每12 h补加10 g/L乳糖和20 g/L甘油,培养至72 h。
发酵培养基配方为:胰蛋白胨2 g/L,酵母提取物4 g/L,甘油20 g/L,磷酸二氢钾13.5 g/L,磷酸氢二铵1.4 g/L,柠檬酸1.7 g/L,七水硫酸镁1.5 g/L,微量元素10 ml/L。微量金属元素中含有水硫酸锌2.25 g/L,硫酸亚铁10 g/L,一水硫酸锰0.35 g/L,无水硫酸铜1.0 g/L,十水硼酸钠0.23 g/L,二水氯化钙2.0 g/L,钼酸铵0.11 g/L。
在摇瓶实验中,大肠杆菌生产乳酰-N-新四糖的能力提升至5.47 g/L,在5 L发酵罐中,产量达到36.46 g / L,为乳酰-N-新四糖的工业化生产奠定了基础。
下面结合附图对本发明方案做出说明,其中,未具体说明操作步骤的实验方法,均按照相应商品说明书进行,实施例中所用到的仪器、试剂、耗材如无特殊说明,均可从商业公司购买得到。
实施例1:高效合成乳酰-N-新四糖的重组大肠杆菌的构建
1.1 重叠延伸PCR扩增片段
(1)lgtA、lgtB基因片段的获得:NCBI下载基因序列,委托苏州金唯智生物科技有限公司进行质粒合成,以合成质粒为模板,设计引物进行PCR扩增。
(2)galE基因片段的获得:以大肠杆菌MG1655基因组为模板,设计引物扩增。
(3)glmU、glnA基因片段的获得:以大肠杆菌BL21基因组为模板,设计引物进行扩增。
1.2 基因敲除与整合
使用λ-Red同源重组进行基因敲除,首先需要在宿主菌BL21(DE3)中导入pKD46质粒,诱导重组酶表达;进而使用含有重组酶的菌进行两步同源重组,使用氯霉素抗性基因与蔗糖敏感基因sacB通过重叠延伸PCR进行融合,第一步用cat-sacB片段置换待缺失基因,电转后涂布氯霉素和庆大霉素双抗平板,筛选出能在平板生长的菌落进行PCR鉴定;第二步利用sacB基因的蔗糖聚合致死作用反筛出不含cat-sacB片段的菌株,再次进行PCR鉴定并测序验证,得到目的基因整合成功的菌株。
利用上述基因编辑方法依次敲除大肠杆菌BL21(DE3)中lacZ, wzzE, manA, ldhA, pflB, sthA glsA, glsB基因,并依次基因组整合表达lgtA, galE-lgtB, glmU,lgtA-lgtB, lgtB, glnA, lgtA, lgtB,最后37℃消除pKD46质粒,得到最终的高产菌株。具体步骤如下:
以BL21(DE3)为出发菌株,敲除β-半乳糖苷酶基因lacZ的表达,并在此位点整合β-1,3-乙酰葡萄糖胺转移酶基因lgtA,获得菌株E0;在菌株E0的基础上,敲除大肠杆菌共同抗原多糖共聚酶基因wzzE的表达,并在此位点整合UDP-葡萄糖4-差向异构酶基因galE及β-1,4-半乳糖基转移酶基因lgtB,得到菌株E1;在菌株E1基础上,敲除甘露糖-6-磷酸异构酶基因manA,并在此位点过表达葡萄糖胺-1-磷酸乙酰转移酶基因glmU,得到菌株E2;在菌株E2基础上,敲除D-乳酸脱氢酶基因ldhA,并在此位点过表达β-1,3-乙酰葡萄糖胺转移酶基因lgtA及β-1,4-半乳糖基转移酶基因lgtB,的的菌株E3;在菌株E3基础上,敲除丙酮酸甲酸裂解酶基因pflB,并在此位点过表达β-1,4-半乳糖基转移酶基因lgtB,得到菌株E4;在菌株E4基础上,敲除吡啶核苷酸转氢酶基因sthA,并在此位点过表达谷氨酰胺合成酶基因glnA,得到菌株E5;在菌株E5基础上,敲除谷氨酰胺酶基因glsA,并在此位点过表达β-1,3-乙酰葡萄糖胺转移酶基因lgtA,得到菌株E6;在菌株E6基础上,敲除谷氨酰胺酶基因glsB,并在此位点过表达β-1,4-半乳糖基转移酶基因lgtB,得到菌株E7。其中获得的菌株E0-E7组成如表1所示,构建各个菌株使用的引物如表2所示。
表1 构建高产乳酰-N-新四糖的重组大肠杆菌过程菌
表2 构建高产乳酰-N-新四糖的重组大肠杆菌所用引物
实施例2:重组工程菌发酵合成乳酰-N-新四糖
分别对实施例1构建得到的E0-E7菌株进行培养和发酵,分别将重组菌株的种子液以5%的接种量接入发酵培养基中,37℃,180 rpm培养,发酵培养基的配方为:胰蛋白胨2 g/L,酵母提取物4 g/L,甘油20 g/L,磷酸二氢钾13.5 g/L,磷酸氢二铵1.4 g/L,柠檬酸1.7g/L,七水硫酸镁1.5 g/L,微量元素10 ml/L,当OD值达到12时,加入10 g/L乳糖,每12 h补加10 g/L乳糖和20 g/L甘油,发酵72 h。微量金属元素中含有水硫酸锌2.25 g/L,硫酸亚铁10 g/L,一水硫酸锰0.35 g/L,无水硫酸铜1.0 g/L,十水硼酸钠0.23 g/L,二水氯化钙2.0g/L,钼酸铵0.11 g/L。
发酵结束后,使用高效液相色谱仪对发酵液中的乳酰-N-新四糖的产量进行测定,乳酰-N-新四糖利用高效液相色谱仪进行检测:HPLC (Waterse2695);色谱柱:Carbohydrate Analysis column(Rezex ROA-organic acid H+(8%)300×7.8 mm);流动相:5 mM H2SO4;流速:0.5 mL/min;检测器:示差检测器;柱温60℃;进样量:10 μL。
高产乳酰-N-新四糖的重组大肠杆菌E0-E7菌株,在摇瓶体系和发酵罐体系中乳酰-N-新四糖表达情况如表3和图3所示,从数据能看出,通过对大肠杆菌的改造,能够显著提升重组大肠杆菌表达乳酰-N-新四糖(LNnT)的能力,尤其是菌株E7,5L发酵罐中重组菌株的乳酰-N-新四糖产量达到36.46 g/L。如图3所示是菌株E7在5L发酵罐中产物、底物动态变化以及生长曲线,从图中能够看出,重组工程菌能够不断消耗底物甘油和乳糖,并随着菌株OD值得升高,目标物乳酰-N-新四糖的表达量显著提升,证明构建得到的重组大肠杆菌能够高产乳酰-N-新四糖。
表3
以上对本发明的实施例进行了详细说明,但所述内容仅为本发明的较佳实施例,不能被认为用于限定本发明的实施范围。凡依本发明申请范围所作的均等变化与改进等,均应仍归属于本发明的专利涵盖范围之内。
Claims (8)
1.一种高效合成乳酰-N-新四糖的重组大肠杆菌,其特征在于:在底盘宿主细胞中插入lgtA和lgtB基因;
敲除其基因组中lacZ, wzzE manA, ldhA, pflB, sthA glsA, glsB基因中的一种或多种,还插入或过表达galE和/或glmU基因。
2.根据权利要求1所述的高效合成乳酰-N-新四糖的重组大肠杆菌,其特征在于:以底盘宿主大肠杆菌为出发菌株,敲除lacZ,并在此位点整合lgtA;敲除wzzE,并在此位点整合galE及lgtB;敲除manA,并在此位点过表达glmU;敲除ldhA,并在此位点过表达lgtA及lgtB;敲除pflB,并在此位点过表达lgtB;敲除sthA,并在此位点过表达glnA;敲除glsA,并在此位点过表达lgtA;敲除glsB,并在此位点过表达lgtB,得到高效合成乳酰-N-新四糖的重组大肠杆菌。
3.根据权利要求2所述的高效合成乳酰-N-新四糖的重组大肠杆菌,其特征在于:整合或过表达基因使用23100启动子进行转录。
4.根据权利要求1-3中任一所述的高效合成乳酰-N-新四糖的重组大肠杆菌,其特征在于:lgtA核苷酸序列如SEQ ID NO.1所示,lgtB核苷酸序列如SEQ ID NO.2所示。
5.一种乳酰-N-新四糖的制备方法,其特征在于:通过权利要求1-4中任一所述的重组大肠杆菌培养并发酵得到。
6.根据权利要求5所述的乳酰-N-新四糖的制备方法,其特征在于:重组大肠杆菌经种子培养获得种子液,再将种子液接种于发酵体系中,获得产乳酰-N-新四糖的发酵液;
种子培养基为LB液体培养基,将种子液接入发酵体系,于37℃,180 rpm条件下,培养至OD600为12时,加入10 g/L乳糖,每12 h补加10 g/L乳糖和20 g/L甘油,培养至72 h。
7.根据权利要求6所述的乳酰-N-新四糖的制备方法,其特征在于:发酵培养基的配方为:胰蛋白胨2 g/L,酵母提取物4 g/L,甘油20 g/L,磷酸二氢钾13.5 g/L,磷酸氢二铵1.4g/L,柠檬酸1.7 g/L,七水硫酸镁1.5 g/L,微量元素10 ml/L。
8.权利要求5-7中任一所述的乳酰-N-新四糖的制备方法制备得到的乳酰-N-新四糖在食品或药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410069807.4A CN117586938B (zh) | 2024-01-18 | 2024-01-18 | 一种合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410069807.4A CN117586938B (zh) | 2024-01-18 | 2024-01-18 | 一种合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117586938A true CN117586938A (zh) | 2024-02-23 |
CN117586938B CN117586938B (zh) | 2024-03-29 |
Family
ID=89913659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410069807.4A Active CN117586938B (zh) | 2024-01-18 | 2024-01-18 | 一种合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117586938B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113652385A (zh) * | 2021-08-06 | 2021-11-16 | 江南大学 | 一种高产乳酰-n-四糖的微生物的构建方法及应用 |
CN113684164A (zh) * | 2021-08-06 | 2021-11-23 | 江南大学 | 一种高产乳酰-n-新四糖的微生物的构建方法及应用 |
CN114990037A (zh) * | 2022-05-24 | 2022-09-02 | 江南大学 | 一种高产乳酰-n-四糖的重组大肠杆菌的构建方法及应用 |
-
2024
- 2024-01-18 CN CN202410069807.4A patent/CN117586938B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113652385A (zh) * | 2021-08-06 | 2021-11-16 | 江南大学 | 一种高产乳酰-n-四糖的微生物的构建方法及应用 |
CN113684164A (zh) * | 2021-08-06 | 2021-11-23 | 江南大学 | 一种高产乳酰-n-新四糖的微生物的构建方法及应用 |
CN114990037A (zh) * | 2022-05-24 | 2022-09-02 | 江南大学 | 一种高产乳酰-n-四糖的重组大肠杆菌的构建方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117586938B (zh) | 2024-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112501106B (zh) | 一种生产2’-岩藻糖基乳糖的大肠杆菌及其应用 | |
US20210254031A1 (en) | Engineered strain for producing allulose and derivatives thereof, method for construction therefor and use thereof | |
CN114480240B (zh) | 一种产岩藻糖基乳糖的基因工程菌及生产方法 | |
JP2022517903A (ja) | フコシル化オリゴ糖の合成 | |
US11761021B2 (en) | Recombinant Bacillus subtilis for synthesizing lacto-N-neotetraose and application thereof | |
CN103045528B (zh) | 生产dl-丙氨酸的工程菌及利用该工程菌生产dl-丙氨酸的方法 | |
CN111548979B (zh) | 合成乳酰n-新四糖的重组大肠杆菌及其构建方法与应用 | |
US20240035057A1 (en) | Construction Method and Application of Microorganism Capable of Realizing High Production of Lacto-N-tetrose | |
CN112625990A (zh) | 一种合成2`-岩藻糖基乳糖的重组大肠杆菌及其构建方法 | |
WO2021128465A1 (zh) | 一种促进N-乙酰氨基葡萄糖生产的RamA转录因子突变体及其应用 | |
CN114874964A (zh) | 一种高产2′-岩藻糖基乳糖的重组大肠杆菌的构建方法及应用 | |
CN112662604A (zh) | 一种合成3-岩藻糖基乳糖的重组大肠杆菌及其构建方法 | |
CN116064345A (zh) | 高效生产岩藻糖基乳糖的无抗基因工程菌及其应用 | |
Zhu et al. | Elimination of byproduct generation and enhancement of 2′-fucosyllactose synthesis by expressing a novel α1, 2-fucosyltransferase in engineered Escherichia coli | |
CN117586938B (zh) | 一种合成乳酰-n-新四糖的重组大肠杆菌的构建方法及应用 | |
JP2023534879A (ja) | N-アセチルグルコサミン産生菌株並びにその構築方法及び使用 | |
CN114806991B (zh) | 一种提高岩藻糖基乳糖产量的工程大肠杆菌及生产方法 | |
CN114672448B (zh) | 一种合成2’-岩藻糖基乳糖的大肠杆菌及其构建方法与应用 | |
CN113957027B (zh) | 一种提高乳酰-n-岩藻六糖产量的基因工程菌及其生产方法 | |
CN113832092B (zh) | 一种提高乳酰-n-岩藻五糖产量的基因工程菌及其生产方法 | |
CN113684163B (zh) | 一种提高乳酰-n-四糖产量的基因工程菌及其生产方法 | |
CN115838682A (zh) | 一种利用甘露聚糖高效生产2′-岩藻糖基乳糖的地衣芽孢杆菌工程菌株 | |
CN116676243A (zh) | 产2'-岩藻糖基乳糖的重组大肠杆菌的构建方法及其应用 | |
CN112501219A (zh) | 一种以蔗糖为原料发酵生产乳酸单体的方法 | |
CN117586937B (zh) | 一种提高乳酰-n-四糖产量的重组大肠杆菌构建及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |